GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (BSP:B1NT34) » Definitions » Cash Receipts from Deposits by Banks and Customers

BioNTech SE (BSP:B1NT34) Cash Receipts from Deposits by Banks and Customers


View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE Cash Receipts from Deposits by Banks and Customers?

Cash Receipts from Deposits by Banks and Customers only applicable to companies reporting Cash Flow from Operations in direct method.


BioNTech SE (BSP:B1NT34) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (BSP:B1NT34) » Definitions » Cash Receipts from Deposits by Banks and Customers
Address
An der Goldgrube 12, Mainz, RP, DEU, D-55131
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.